SYSTEMIC SCLEROSIS

This study tests whether baricitinib, an oral drug, can reduce skin thickening in people with systemic sclerosis, a rare autoimmune disease. About 60 adults with early diffuse disease will receive either baricitinib or a placebo for 24 weeks. The main goal is to measure changes i…

This study tests a drug called anifrolumab against a placebo in 314 adults with systemic sclerosis (scleroderma), a disease that causes skin and organ scarring. Participants receive injections and are monitored for improvements in skin tightness, lung function, and daily activiti…

This early-phase study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and attack faulty cells in active autoimmune diseases like lupus, scleroderma, and Sjögren's syndrome. The goal is to see if it is safe and tolerable for up to …

This early-stage study tests a new treatment called KYV-101 for people with systemic sclerosis, a disease where the immune system attacks the body, causing skin and organ damage. The therapy uses a patient's own immune cells, modified to target and destroy harmful B cells. The ma…

This study tests a new drug called CM-101 in about 45 adults with systemic sclerosis, a disease that causes hardening of the skin and can affect internal organs. The goal is to see if the drug is safe and tolerable. Participants will receive either CM-101 or a placebo, and resear…

This study tests a new treatment using donor immune cells (CAR T-cells) that are engineered to target and calm the overactive immune system in people with severe lupus or scleroderma. The goal is to see if it is safe and can control the disease. The trial involves 18 adults whose…

This early-phase study tests KITE-363, a personalized therapy where a patient's own immune cells are modified to target and attack faulty B cells that drive autoimmune diseases like lupus and scleroderma. About 52 adults with severe, treatment-resistant forms of these conditions …

This early-stage study tests a new treatment for people with severe lupus or scleroderma that hasn't improved with standard therapies. The treatment uses a person's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety and fi…

This study tests an experimental drug called MT-0551 against a placebo in 80 adults with systemic sclerosis, a disease that causes skin thickening and can affect internal organs. The main goal is to see if the drug reduces skin hardness over 26 weeks. Researchers will also check …

This study looks at whether the Shingrix vaccine is safe and effective for preventing shingles in people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus. About 2,000 patients will receive the vaccine or a placebo, and researchers will monitor for disease fl…

This study tests whether a fecal microbiota transplant (FMT) can safely improve chronic diarrhea in people with systemic sclerosis, an autoimmune disease. Twenty adults will receive either FMT or a placebo, and researchers will track side effects and symptom changes. The goal is …

This study looks at whether giving people with inflammatory arthritis extra help—like a list of local resources, a community specialist, or a nurse navigator—can reduce missed doctor visits. About 100 adults who have missed appointments in the past year and have social needs (lik…

This study looks at CT scans from 1000 people with systemic sclerosis (a disease that can cause lung scarring) to see if computer analysis can predict who will get worse. Researchers will check if certain patterns in the lungs, airways, and blood vessels can forecast breathing de…

This study planned to collect extra blood and urine samples from scleroderma patients during their regular check-ups to find biological markers that could predict if their disease would get worse over the next 10 years. The goal was to improve treatment decisions and identify the…